JP2023505441A5 - - Google Patents

Info

Publication number
JP2023505441A5
JP2023505441A5 JP2022532697A JP2022532697A JP2023505441A5 JP 2023505441 A5 JP2023505441 A5 JP 2023505441A5 JP 2022532697 A JP2022532697 A JP 2022532697A JP 2022532697 A JP2022532697 A JP 2022532697A JP 2023505441 A5 JP2023505441 A5 JP 2023505441A5
Authority
JP
Japan
Prior art keywords
seq
amino acid
group
functional
fatty acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022532697A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023505441A (ja
JP7788376B2 (ja
Filing date
Publication date
Priority claimed from PCT/EP2019/083506 external-priority patent/WO2020115048A1/en
Application filed filed Critical
Priority claimed from PCT/EP2020/084487 external-priority patent/WO2021110845A1/en
Publication of JP2023505441A publication Critical patent/JP2023505441A/ja
Publication of JP2023505441A5 publication Critical patent/JP2023505441A5/ja
Priority to JP2025141835A priority Critical patent/JP2025172864A/ja
Application granted granted Critical
Publication of JP7788376B2 publication Critical patent/JP7788376B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022532697A 2019-12-03 2020-12-03 最適化されたｇｉｐペプチド類縁体 Active JP7788376B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025141835A JP2025172864A (ja) 2019-12-03 2025-08-28 最適化されたｇｉｐペプチド類縁体

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
PCT/EP2019/083506 WO2020115048A1 (en) 2018-12-03 2019-12-03 Modified gip peptide analogues
EPPCT/EP2019/083506 2019-12-03
EP20179259.5 2020-06-10
EP20179259 2020-06-10
PCT/EP2020/084487 WO2021110845A1 (en) 2019-12-03 2020-12-03 Optimized gip peptide analogues

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025141835A Division JP2025172864A (ja) 2019-12-03 2025-08-28 最適化されたｇｉｐペプチド類縁体

Publications (3)

Publication Number Publication Date
JP2023505441A JP2023505441A (ja) 2023-02-09
JP2023505441A5 true JP2023505441A5 (enExample) 2023-12-12
JP7788376B2 JP7788376B2 (ja) 2025-12-18

Family

ID=71083547

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022532697A Active JP7788376B2 (ja) 2019-12-03 2020-12-03 最適化されたｇｉｐペプチド類縁体
JP2025141835A Pending JP2025172864A (ja) 2019-12-03 2025-08-28 最適化されたｇｉｐペプチド類縁体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025141835A Pending JP2025172864A (ja) 2019-12-03 2025-08-28 最適化されたｇｉｐペプチド類縁体

Country Status (10)

Country Link
US (1) US20250346647A2 (enExample)
EP (1) EP4069719A1 (enExample)
JP (2) JP7788376B2 (enExample)
KR (1) KR20220108064A (enExample)
CN (1) CN114761420B (enExample)
AU (1) AU2020398675A1 (enExample)
CA (1) CA3157387A1 (enExample)
IL (1) IL293249A (enExample)
MX (1) MX2022006737A (enExample)
WO (1) WO2021110845A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3221661A1 (en) * 2021-06-10 2022-12-15 Alexander HOVARD SPARRE-ULRICH Treatment of obesity and obesity-related disorders
WO2023139106A2 (en) * 2022-01-18 2023-07-27 Novo Nordisk A/S Long-acting gipr antagonists
EP4556487A1 (en) * 2022-07-13 2025-05-21 Hangzhou Zhongmeihuadong Pharmaceutical Co., Ltd. Glp-1/gip dual agonist, and preparation method therefor and use thereof
TW202529796A (zh) * 2023-11-22 2025-08-01 大陸商杭州中美華東製藥有限公司 Glp-1r/gipr雙標靶激動劑在製備動物藥的用途
WO2025259957A1 (en) * 2024-06-14 2025-12-18 Eli Lilly And Company Compositions and methods for improving insulin sensitivity

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8263545B2 (en) * 2005-02-11 2012-09-11 Amylin Pharmaceuticals, Inc. GIP analog and hybrid polypeptides with selectable properties
CN101155828A (zh) * 2005-02-11 2008-04-02 安米林药品公司 Gip类似物和具有可选择性质的杂合多肽
KR20070115947A (ko) * 2005-02-11 2007-12-06 아밀린 파마슈티칼스, 인크. 선택가능한 특성들을 가지는 ｇｉｐ 유사체 및 하이브리드폴리펩타이드
WO2008021560A2 (en) * 2006-08-17 2008-02-21 Amylin Pharmaceuticals, Inc. Dpp-iv resistant gip hybrid polypeptides with selectable properties
WO2010016940A2 (en) * 2008-08-07 2010-02-11 Ipsen Pharma S.A.S. Analogues of glucose-dependent insulinotropic polypeptide
ES2574835T3 (es) * 2008-08-07 2016-06-22 Ipsen Pharma S.A.S. Análogos del polipéptido insulinotrópico dependiente de glucosa
WO2010016936A1 (en) * 2008-08-07 2010-02-11 Ipsen Pharma S.A.S. Pharmaceutical compositions of analogues of glucose-dependent insulinotropic polypeptide
CN107129538B (zh) * 2010-04-27 2021-07-16 西兰制药公司 Glp-1受体激动剂和胃泌素的肽缀合物及其用途
IN2014MN02304A (enExample) * 2012-05-03 2015-08-07 Zealand Pharma As
ES2685987T3 (es) * 2014-09-05 2018-10-15 University Of Copenhagen Análogos de péptidos gip
KR102743887B1 (ko) * 2017-05-31 2024-12-19 유니버시티 오브 코펜하겐 장기-작용성 gip 펩타이드 유사체
AR113486A1 (es) * 2017-12-21 2020-05-06 Lilly Co Eli Análogos de incretina y sus usos
SG11202105586YA (en) * 2018-12-03 2021-06-29 Antag Therapeutics Aps Modified gip peptide analogues

Similar Documents

Publication Publication Date Title
JP2023505441A5 (enExample)
JP2022509568A5 (enExample)
JP7658877B2 (ja) インクレチン類似体およびその使用
JP7605747B2 (ja) 修飾されたｇｉｐペプチド類似体
CN103596583B (zh) 新型胰高血糖素类似物
JP2025172864A5 (enExample)
JP6054742B2 (ja) アシル化グルカゴン類似体
JP5635529B2 (ja) グルカゴン類似体
KR102824306B1 (ko) 인크레틴 유사체 및 그의 용도
JP7443315B2 (ja) アシル化オキシントモジュリンペプチド類似体
JP2011502159A5 (enExample)
TW201716431A (zh) 升糖素及ｇｌｐ－１共激動劑化合物
CN119119235A (zh) 酰化胰高血糖素类似物
AU2011206979A1 (en) Treatment of cardiac conditions
WO2009142307A1 (ja) 目的ペプチドの血漿中半減期延長作用を有するペプチド
KR20110040760A (ko) 대사 질환 및 비만 치료용 ｇｉｐ-기초된 혼합형 항진제
JP2024521398A5 (enExample)
JP2012506402A5 (enExample)
CA2931694C (en) Fatty acid derivatives of dimeric peptide ligands of psd-95 and use thereof for treating excitotoxic disease
JP2020521784A5 (enExample)
JP7440663B2 (ja) 長時間作用型ｇｌｐ－１およびグルカゴン受容体デュアルアゴニスト
JP2011525895A (ja) アミリン及びサケカルシトニンの誘導体化ハイブリッドペプチド
RU2022116575A (ru) Оптимизированные пептидные аналоги gip
EP4547703A1 (en) Amylin receptor (hamy3r) agonists with improved chemical stability
EA050089B1 (ru) Полипептиды и варианты их применения